Former Pfizer Execs Shop L/S Equity Hedge Fund

Jul 16 2007 | 6:11am ET

Groton, Conn.-based Do Asset Management has begun marketing its $10 million equity long/short fund to outside investors, with the goal of reaching $250 million by year-end.   

The fund, which launched in October 2004, is derived from the firm’s foundation as a provider of valuation and risk management to the pharmaceutical, biotech, and energy sectors. “The fund was started to apply our know-how of private asset valuation in the public markets,” said co-founder Gill Eapen. “We have a long/short strategy that tends to be market neutral and we don’t take any sector or size exposure. We don’t generally buy beta risk [instead] going after alpha.”

Eapen added that the fund can be customized for either institutional investors looking for low beta returns or high-net worth investors seeking absolute returns. The fund is being shopped by third-party marketer Alpha Introductions. 

The long/short offering, DoAM’s flagship, returned 22% on an annualized basis and 9.4% YTD. Its 1:1 levered version has fared even better, with a 25.4% annualized return and 14.6% YTD. The fund charges 2% for management and 20% for performance, with a $500,000 for investments in the fund and $3 million to $5 million for separately-managed accounts.

Eapen is a former group director of Pfizer, responsible for the company’s portfolio management. Former Pfizer executives Pierre Etienne, Dilip Mehta, Craig Saxton and Ian Williams round out DoAM’s management team.


In Depth

Delayed Flash Crash Arrest Highlights Difficulties Detecting Fraud

Apr 23 2015 | 7:19am ET

The five years it took regulators to bring high-profile charges against a UK trader...

Lifestyle

Puerto Rico Woos The Rich But So Far Gains Little

Apr 17 2015 | 2:45am ET

Hedge fund manager Rob Rill grins. He has just had word that U.S. financial regulators...

Guest Contributor

Opportunities Ahead: Asian Fixed Income and Currency Markets

Apr 24 2015 | 6:18am ET

For hedge funds focusing on Asia, the policy uncertainty, unclear interest rate...

 

Editor's Note